Paul Lyne

Paul Lyne is an accomplished leader in oncology with extensive experience in research and development. Currently serving as the Global Head of Oncology Research Unit at EMD Serono, Inc. since October 2022, Paul has previously held significant roles at the Healthcare Business of Merck, including Global Head of R&D Strategy, Portfolio and Innovation, and Head of Oncology Development Unit. Additionally, during a tenure at AstraZeneca spanning from 2001 to September 2018, Paul led various oncology programs and teams, driving strategic direction and delivery of oncology assets from late discovery through clinical development. Paul began a scientific career with roles at Biogen Idec and held academic positions at prestigious institutions such as Harvard University and the University of Oxford, complementing a strong educational background in biophysics and chemistry.